PositiveID Corporation (fka PSID)

[greaseyfingers]

Complete-the-license and/or sale of the VeriChip and iglucose-product-lines to position them with the best partners for market exploitation and monetization..

Complete strategic financing to capitalize the Company to execute on these opportunities..

William J. Caragol, Chairman and CEO of PositiveID, stated, "We continue to focus on our molecular diagnostic business and are excited about the significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of our innovative Dragonfly system. We are very proud of our accomplishments year to date and will continue to execute our plan, described above. We believe that we are well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products. That progress, in conjunction with a strategic financing to fully capitalize the Company, we believe, will allow us to unlock value for stockholders."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79489442